[Study of S-6437 in pediatrics regarding clinical efficacy, blood levels and urinary excretion (author's transl)]. 1977

S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano

S-6437 was orally given to 29 patients of 3 months to 12 years and 6 months of age who had respiratory or urinary tract infections. The daily dose used was 25 to 60 mg/kg divided in two doses. The following is the results of this study: 1. With 25 approximately 60 mg/kg/day, satisfactory results were obtained for upper respiratory tract infections. In lower respiratory tract infections, however, the effectiveness seemed not to be so good as that in upper respiratory tract infections. 2. Side effects such as diarrhea, loose stool, abdominal pain and eruption were observed but they were temporary. Therefore, the administration of S-6437 was not discontinued due to such side effects. 3. S-6437 was acceptable to elder children but some of children of 2 approximately 4 years of age disliked this preparation because it was not smooth in their mouths. Therefore, the preparation of S-6437 should be further improved. 4. Since it has been recognized that blood levels of cephalexin following the administration of S-6437 last for a longer period of time than regular cephalexin, S-6437 is considered to be a useful preparation. 5. B.I.D. and T.I.D. regimens of S-6437 will give clinical satisfaction to children over 6 years and ones under 6 years, respectively.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
September 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
September 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
September 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
September 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
February 1978, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
December 1981, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
September 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
December 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
November 1977, The Japanese journal of antibiotics,
S Nanri, and K Sunagawa, and N Hara, and K Kimura, and M Osano
November 1977, The Japanese journal of antibiotics,
Copied contents to your clipboard!